US FDA Approves IMAAVY as First Treatment for Warm Autoimmune Hemolytic Anemia
The US Food and Drug Administration (FDA) has approved IMAAVY (nipocalimab-aahu) as the first treatment for warm autoimmune hemolytic anemia, based on durable hemoglobin responses in phase 2/3.
Karen Jones | 26/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy